The use of hemospray in portal hypertensive bleeding; a case series

J Hepatol. 2014 Feb;60(2):457-60. doi: 10.1016/j.jhep.2013.10.008. Epub 2013 Oct 17.

Abstract

Hemospray is a haemostatic agent licensed for endoscopic haemostasis of non-variceal upper gastrointestinal bleeding (NVUGIB) in Europe and Canada. Hemospray has been shown to be safe and effective in achieving haemostasis in bleeding peptic ulcers in a prospective clinical study and several further case series have described the use of hemospray in other non-variceal causes of gastrointestinal bleeding. Portal hypertensive gastropathy and colopathy are common in patients with portal hypertension. As hemospray is an easy to apply, non-contact method, which can cover large areas of mucosa, it may be of benefit in acute non-variceal portal hypertensive bleeding. We present data from the first four consecutive patients presenting to our institution with acute haemorrhage secondary to non-variceal diffuse portal hypertensive bleeding treated with hemospray.

Keywords: Endoscopic hemostasis; Gastrointestinal bleeding; Portal hypertension.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Gastrointestinal Hemorrhage / etiology*
  • Gastrointestinal Hemorrhage / therapy*
  • Hemostasis, Endoscopic / methods
  • Hemostatics / administration & dosage*
  • Humans
  • Hypertension, Portal / complications*
  • Liver Cirrhosis / complications
  • Male
  • Minerals / administration & dosage*
  • Powders / administration & dosage

Substances

  • Hemostatics
  • Minerals
  • Powders
  • hemospray